venBio Partners
venBio Partners reported 9 stocks worth $496M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PBLS (34.3%), PHVS (28.5%) and ATTO (14.4%). Compared with Q2 2026, the fund opened new positions in ATTO, YARW and LSTA, trimmed PHVS and ALMS and sold out of HRMY.
Latest filing: what venBio Partners did in Q3 2026
vs Q2 2026None
HRMY$17.2M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PBLS Parabilis Medicines Inc Com | $170M | 34.3% | 5.3M | No change | 2 of 8 | |
| 2 | ![]() PHVS Pharvaris N V | $141M | 28.5% | 4.5M | −184K (−4%) | 8 of 8 | |
| 3 | ![]() ATTO Attovia Therapeutics Inc | $71.7M | 14.4% | 4.2M | New position | 1 of 8 | |
| 4 | ![]() ACHV Achieve Life Sciences Inc | $47.9M | 9.7% | 5.9M | No change | 2 of 8 | |
| 5 | ![]() ALMS Alumis Inc | $31M | 6.3% | 4.2M | −337K (−7%) | 8 of 8 | |
| 6 | ![]() ALXO Alx Oncology Hldgs Inc | $17.9M | 3.6% | 12.9M | No change | 8 of 8 | |
| 7 | ![]() YARW Yarrow Bioscience Inc | $12.5M | 2.5% | 555K | New position | 1 of 8 | |
| 8 | ![]() LYEL Lyell Immunopharma Inc | $3.3M | 0.7% | 338K | No change | 6 of 8 | |
| 9 | ![]() LSTA Lisata Therapeutics Inc | $225K | 0.1% | 156K | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() HRMY Harmony Biosciences Hldg | $17.2M | 472K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →venBio Partners 13F FAQ
What does venBio Partners own?
venBio Partners reported 9 stocks worth $496M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PBLS (34.3%), PHVS (28.5%) and ATTO (14.4%). The table above lists every position in the filing (the top 10 without an account).
What did venBio Partners buy and sell in Q3 2026?
Compared with Q2 2026: 3 new positions, 0 added to, 2 trimmed and 1 sold out. New positions include ATTO, YARW and LSTA. It sold all of HRMY.
When will venBio Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is venBio Partners's portfolio worth?
The Q3 2026 filing reports $496M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.








